Inventiva Sa (IVA NASDAQ) stock market data APIs
$4.8709
0.11(2.3%)
as of October 17, 2025
Try our APIs with
free plan!
Inventiva Sa Financial Data Overview
Price chart is built with
Anychart
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Prev. Close
4.8709
Open
4.9782
High
5.035
Low
4.7454
52 wk Range
2.1112-6.5469
Market Cap
761 M
Shares Outstanding
139 M
Revenue
16 970 K
EPS
0
Beta
0.747
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inventiva Sa data using free add-ons & libraries
Get Inventiva Sa Fundamental Data
Inventiva Sa Fundamental data includes:
- Net Revenue: 16 970 K
- EBITDA: -95 789 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-29
- EPS/Forecast: -0.6048
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inventiva Sa News
New
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical comp...
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM)
Daix (France), New York City (New York, Etats-Unis), le 14 octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisé...
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibra...
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025
Présentation d’une comparaison entre histologie numérique et sur lame des biopsies de screening de l’étude de Phase 3 NATiV3 Présentation de pathologie numérique de données précliniques ave...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
